Next Science

Next Science Accounts Payable

Delisted

The Accounts Payable of Next Science (NXS.AX) as of Oct 28, 2026 is 928,100.00 USD. In the previous year, Accounts Payable was 1.41 M USD — a change of -34.22% (lower).

Accounts Payable

928,100.00USD

YoY

-34.22%

Last updated:

Accounts Payable of Next Science is 2024 928,100.00 USD. Accounts Payable of Next Science was 2023 1.41 M USD. It decreases by -34.22% lower compared to the previous year.

The Next Science Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2017
379,200.00 USD
Jan 1, 2018
522,100.00 USD
Jan 1, 2019
628,000.00 USD
Jan 1, 2020
571,500.00 USD
Jan 1, 2021
515,600.00 USD
Jan 1, 2022
973,700.00 USD
Jan 1, 2023
1.41 M USD
Jan 1, 2024
928,100.00 USD
The Next Science Accounts Payable history
YEARAccounts PayableYoY
928,100.00USD-34.22%
1.41 MUSD+44.91%
973,700.00USD+88.85%
515,600.00USD-9.78%
571,500.00USD-9.00%
628,000.00USD+20.28%
522,100.00USD+37.68%
379,200.00USD+117.18%
174,600.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Next Science Stock analysis

What does Next Science do? Next Science Ltd. generates revenue through the development and commercialization of its XBIO technology, which addresses bacterial biofilm-related infections in human health. The company's product portfolio includes XPERIENCE, a solution for preventing surgical site infections by rinsing away debris and microorganisms, and SurgX Sterile Antimicrobial Gel, designed to reduce surgical and post-surgical infections through sustained antibacterial action for up to five days. Blast X, an antimicrobial wound gel, targets bacterial infections in wounds. These products are sold to healthcare providers and medical facilities seeking effective solutions for bacterial biofilm eradication and infection prevention. The XBIO technology underpins all products, offering non-toxic efficacy against both biofilm and free-floating bacteria. XPERIENCE is used as a pre-surgical rinse, SurgX provides prolonged protection post-surgery, and Blast X treats existing wounds. Healthcare institutions, particularly hospitals and surgical centers, are the primary buyers, leveraging these products to enhance patient outcomes and reduce infection rates. Next Science Ltd. focuses on the healthcare sector, specifically targeting applications where bacterial biofilms pose significant risks. The company's products are positioned for use in surgical settings, wound care, and infection prevention protocols. By addressing critical needs in medical environments, the firm caters to healthcare providers who prioritize non-toxic, effective antimicrobial solutions for patient safety and operational efficiency. Next Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Next Science stock

Accounts Payable of Next Science is 928,100.00 USD in 2024.

Accounts Payable of Next Science changed from 1.41 M USD to 928,100.00 USD, representing a -34.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Next Science since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Next Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Next Science

All Key Metrics — Next Science